for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aimmune Therapeutics Inc

AIMT.OQ

Latest Trade

22.79USD

Change

0.13(+0.57%)

Volume

136,202

Today's Range

22.50

 - 

23.04

52 Week Range

16.97

 - 

36.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
22.66
Open
22.70
Volume
136,202
3M AVG Volume
18.63
Today's High
23.04
Today's Low
22.50
52 Week High
36.12
52 Week Low
16.97
Shares Out (MIL)
62.67
Market Cap (MIL)
1,420.08
Forward P/E
-5.64
Dividend (Yield %)
--

Next Event

Aimmune Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Aimmune Therapeutics Qtrly Loss Per Share $1.01

Aimmune "Cautions Stakeholders Against Drawing Conclusions" From ICER's Report On Emerging Desensitization Treatments For Peanut Allergy

Aimmune Therapeutics Reports Q1 Loss Per Share $0.87

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aimmune Therapeutics Inc

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

Industry

Biotechnology & Drugs

Contact Info

8000 Marina Blvd Ste 300

+1.650.6145220

http://www.aimmune.com/

Executive Leadership

Mark D. McDade

Independent Chairman of the Board

Jayson Dallas

President, Chief Executive Officer, Director

Eric H. Bjerkholt

Chief Financial Officer

Mary M. Rozenman

Senior Vice President - Corporate and Strategy Development

Douglas T. Sheehy

General Counsel, Secretary

Key Stats

2.00 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.890

2017

-2.610

2018

-3.670

2019(E)

-4.017
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
6.93
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
18.80
LT Debt To Equity (MRQ)
18.80
Return on Investment (TTM)
-82.71
Return on Equity (TTM)
-72.22

Latest News

BRIEF-Aimmune Therapeutics Announces Closing Of $98 Mln Investment By Nestlé Health Science

* AIMMUNE THERAPEUTICS ANNOUNCES CLOSING OF $98 MILLION INVESTMENT BY NESTLÉ HEALTH SCIENCE

Nestle raises stake in food allergy drug developer Aimmune

The health science arm of Nestle SA will pay $98 million to raise its stake in Aimmune Therapeutics Inc, the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.

BRIEF-Aimmune Therapeutics Announces Additional Equity Investment By Nestlé Health Science

* AIMMUNE THERAPEUTICS ANNOUNCES ADDITIONAL EQUITY INVESTMENT BY NESTLÉ HEALTH SCIENCE

Nestle raises stake in food allergy drug developer Aimmune

The health science unit of Nestle SA would pay $98 million to increase its stake in Aimmune Therapeutics Inc, the drug developer for food allergies said on Monday.

BRIEF-Aimmune Therapeutics Reports Q1 Loss Per Share $0.92

* AIMMUNE THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Aimmune Therapeutics Qtrly Loss Per Share $0.81

* AIMMUNE THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock

* AIMMUNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Aimmune's peanut allergy drug meets main goal, shares surge

U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy

* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY

Aimmune's peanut allergy drug meets main goal of key study

U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.

BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment

* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY

BRIEF-Aimmune Therapeutics Inc Files For Potential Mixed Shelf

* AIMMUNE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2ClRCUj) Further company coverage:

BRIEF-Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​

* Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

BRIEF-Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65

* Aimmune Therapeutics announces second quarter 2017 financial results

BRIEF-Aimmune enrolls first patient in Artemis European Phase 3 clinical trial

* Aimmune Therapeutics enrolls first patient in Artemis (ARC010) European Phase 3 clinical trial of AR101 for the treatment of peanut allergy Source text for Eikon: Further company coverage:

BRIEF-Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

* Aimmune Therapeutics reports on up-dosing in its ongoing phase 3 palisade trial of ar101 for peanut allergy

BRIEF-Aimmune Therapeutics enrolls first patient in late-stage trial of its peanut allergy drug

* Aimmune Therapeutics enrolls first patient in ramses (arc007), a phase 3 clinical trial of ar101 for the treatment of peanut allergy

BRIEF-Aimmune Therapeutics reports Q1 loss per share $0.52

* Aimmune therapeutics announces first quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up